These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32794242)

  • 1. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation.
    Castleman JS; Moise KJ; Kilby MD
    Br J Haematol; 2021 Feb; 192(3):425-432. PubMed ID: 32794242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perinatal outcomes of intrauterine transfusion for foetal anaemia due to red blood cell alloimmunisation.
    Şavkli AÖ; Çetin BA; Acar Z; Özköse Z; Behram M; Çaypinar SS; Tayyar A; Yüksel MA
    J Obstet Gynaecol; 2020 Jul; 40(5):649-653. PubMed ID: 31462132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome.
    Zwiers C; van Kamp I; Oepkes D; Lopriore E
    Expert Rev Hematol; 2017 Apr; 10(4):337-344. PubMed ID: 28277805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nipocalimab in Early-Onset Severe Hemolytic Disease of the Fetus and Newborn.
    Moise KJ; Ling LE; Oepkes D; Tiblad E; Verweij EJTJ; Lopriore E; Smoleniec J; Sachs UJ; Bein G; Kilby MD; Miller RS; Devlieger R; Audibert F; Emery SP; Markham K; Norton ME; Ocón-Hernández O; Pandya P; Pereira L; Silver RM; Windrim R; Streisand JB; Leu JH; Mirza A; Smith V; Schwartz LB; Tjoa ML; Saeed-Khawaja S; Komatsu Y; Bussel JB;
    N Engl J Med; 2024 Aug; 391(6):526-537. PubMed ID: 39115062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn.
    Zwiers C; van der Bom JG; van Kamp IL; van Geloven N; Lopriore E; Smoleniec J; Devlieger R; Sim PE; Ledingham MA; Tiblad E; Moise KJ; Gloning KP; Kilby MD; Overton TG; Jørgensen DS; Schou KV; Paek B; Walker M; Parry E; Oepkes D; de Haas M
    Am J Obstet Gynecol; 2018 Sep; 219(3):291.e1-291.e9. PubMed ID: 29902448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation for early-onset haemolytic disease of the fetus/newborn: Can we delay the need for intrauterine transfusions?
    Moise KJ
    Br J Haematol; 2023 Jan; 200(1):11-12. PubMed ID: 36128877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation.
    Vlachodimitropoulou E; Lo TK; Bambao C; Denomme G; Seaward GR; Windrim R; Tessier F; Kelly E; Van Mieghem T; Ryan G
    Br J Haematol; 2023 Jan; 200(1):100-106. PubMed ID: 36100813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion.
    Nwogu LC; Moise KJ; Klein KL; Tint H; Castillo B; Bai Y
    Transfusion; 2018 Mar; 58(3):677-684. PubMed ID: 29250791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful management of severe Kell alloimmunization in pregnancy with intravenous immune globulin.
    Patris M; Holoye A; Goldman D; De Coninck C; Colard M
    Transfus Apher Sci; 2024 Apr; 63(2):103868. PubMed ID: 38238203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion.
    Vlachodimitropoulou E; Garbowski M; Anne Solomon S; Abbasi N; Seaward G; Windrim R; Keunen J; Kelly E; Van Mieghem T; Shehata N; Ryan G
    Br J Haematol; 2022 Feb; 196(4):1096-1104. PubMed ID: 34862601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic plasma exchange and intravenous immunoglobulin as primary therapy for D alloimmunization in pregnancy precludes the need for intrauterine transfusion.
    Bellone M; Boctor FN
    Transfusion; 2014 Aug; 54(8):2118-21. PubMed ID: 24673470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: evaluation of the Dutch national screening programme.
    Slootweg YM; Koelewijn JM; van Kamp IL; van der Bom JG; Oepkes D; de Haas M
    BJOG; 2016 May; 123(6):955-63. PubMed ID: 26661943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting anaemia and transfusion dependency in severe alloimmune haemolytic disease of the fetus and newborn in the first 3 months after birth.
    Ree IMC; de Haas M; Middelburg RA; Zwiers C; Oepkes D; van der Bom JG; Lopriore E
    Br J Haematol; 2019 Aug; 186(4):565-573. PubMed ID: 31140599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn.
    Komatsu Y; Verweij EJTJ; Tiblad E; Lopriore E; Oepkes D; Agarwal P; Lam E; Leu JH; Ling LE; Nelson RM; Olusajo V; Saeed-Khawaja S; Tjoa ML; Zhou J; Amin U; Sirah W; Moise KJ
    Am J Perinatol; 2024 Sep; ():. PubMed ID: 39197469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal risk factors associated with severity of haemolytic disease of the foetus and newborn due to Rhc maternal-foetal incompatibility: A retrospective cohort study.
    Franchinard L; Maisonneuve E; Friszer S; Toly Ndour C; Huguet-Jacquot S; Maurice P; Mailloux A; Cortey A; Jouannic JM
    Vox Sang; 2022 Apr; 117(4):570-579. PubMed ID: 34743337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rhesus incompatible pregnancy and its consequences for affected fetuses and neonates.
    Tyndall C; Cuzzilla R; Kane SC
    Transfus Apher Sci; 2020 Oct; 59(5):102948. PubMed ID: 33008742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: IVIG - Is it the answer? Maternal administration of immunoglobulin for severe red cell alloimmunisation during pregnancy: a case series. Connan K, Kornman L, Savoia H et al. 2009; 49: 612-618.
    Smoleniec J
    Aust N Z J Obstet Gynaecol; 2010 Aug; 50(4):406-7. PubMed ID: 20716274
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravenous immunoglobulin as primary therapy or adjuvant therapy to intrauterine fetal blood transfusion: a new approach in the management of severe Rh-immunization.
    Deka D; Buckshee K; Kinra G
    J Obstet Gynaecol Res; 1996 Dec; 22(6):561-7. PubMed ID: 9037945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on HDFN: new information on long-standing controversies.
    Eder AF
    Immunohematology; 2006; 22(4):188-95. PubMed ID: 17430078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of compensatory erythropoiesis in hemolytic disease of the fetus and newborn due to intrauterine transfusions.
    Ree IMC; Lopriore E; Zwiers C; Böhringer S; Janssen MWM; Oepkes D; De Haas M
    Am J Obstet Gynecol; 2020 Jul; 223(1):119.e1-119.e10. PubMed ID: 31978433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.